Pamela S. Diaz - Concepedia

Author

Pamela S. Diaz

Also Known As

P Diaz, P S Diaz, P. Diaz, P. S. DIAZ, P. S. Diaz, PAMELA DIAZ, PAMELA S. DIAZ, Pamela Diaz, Pamela S Diaz, Pamela S. Diaz

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Stanford University Chicago Department of Public Health Centers for Disease Control and Prevention University of Arkansas at Little Rock The Ohio State University

About

Pamela S. Diaz is an author at Stanford University specializing in medicine, infection control, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	683
2	Epidemiology	6	6	190
3	Public Health	4	4	126
4	Health Sciences	1	1	30
5	Allergy	1	1	73

Pamela S. Diaz

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections David W. Kimberlin, Chin‐Yu Lin, Richard F. Jacobs, PEDIATRICS	2001	572
Natural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir Era David W. Kimberlin, Chin‐Yu Lin, Richard F. Jacobs, PEDIATRICS	2001	506
Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a Phase I/II trial David W. Kimberlin, Dwight A. Powell, William C. Gruber, The Pediatric Infectious Disease Journal	1996	156
Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype Ann M. Arvin, Margaret Sharp, Steven G. Smith, The Journal of Immunology	1991	125
Clinical and Microbiological Features of Infection with Malassezia pachydermatis in High-Risk Infants P A Mickelsen, M. C. Viano-Paulson, David A. Stevens, The Journal of Infectious Diseases	1988	100
Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pamela S. Diaz, D Au, S J Smith, PubMed VaccinologyVaccine SafetyVaccinationVaccine DevelopmentVaricella-zoster Virus	1991	96
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. A Arvin, Elaine Kinney-Thomas, K Shriver, The Journal of Immunology Gp IiiMolecular VirologyVzv ProteinsViral PersistencePathogenesis	1986	86
Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization C. M. Koropchak, Suzanne M. Solem, Pamela S. Diaz, Journal of Virology Diagnostic VirologyMolecular VirologyViral DiagnosticsNeurovirologyPathogenesis	1989	82
Outbreak of Adenovirus Genome Type 7d2 Infection in a Pediatric Chronic-Care Facility and Tertiary-Care Hospital Susan I. Gerber, Dean D. Erdman, Stacy Pur, Clinical Infectious Diseases Virus EpidemiologyAdenovirus Type 7Hospital MedicinePediatric EpidemiologyHealthcare-associated Infection	2001	80
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. Pamela S. Diaz, Stephen M. Smith, Elizabeth Hunter, The Journal of Immunology ImmunologyPrimary Vzv InfectionImmunotherapyVzv AgVaccine Target	1989	73

Page 1